Hyperthermic Intraperitoneal Chemotherapy (HIPEC) treatment is reshaping the way doctors fight advanced abdominal cancers.
Unlike traditional systemic chemotherapy, HIPEC delivers high-dose heated drugs directly into the abdomen after cytoreductive surgery. By combining these two approaches, patients receive a treatment designed to destroy cancer cells where they are most aggressive – the abdominal lining [1].
Booking Health, an international leader in medical tourism, is offering international patients expanded access to HIPEC treatment in leading German hospitals. This means that patients from all around the globe can now benefit from advanced cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, achieving both extended survival and improved quality of life.
About HIPEC and Its Benefits for Patients
As mentioned above, HIPEC is performed immediately after cytoreductive surgery, which removes visible tumors from the abdominal cavity. Once the surgery is complete, the abdomen is filled with a heated chemotherapy solution that circulates for 60-90 minutes. This targeted approach allows for higher local effectiveness against cancer cells while minimizing side effects in the rest of the body [1].
This therapy is unique because it:
- Targets cancer cells left after surgery.
- Uses hyperthermia to improve chemotherapy penetration.
- Reduces systemic side effects compared to traditional chemotherapy.
Effects of Hyperthermia on Cancer Cells
| Temperature (°C) | Effect on Cells | Combination with Chemotherapy | Immune Reaction |
| 39-41 (Mild) | Minimal growth arrest | Moderate | Enhanced |
| 41-43 (Moderate) | Growth arrest, improved drug penetration | High | Enhanced |
| >43 (Severe) | High cytotoxicity to normal cells | Excessive | Suppressed |
However, it is important to note that not all patients are candidates for HIPEC. Clinical research shows that this therapy is especially effective in cancers that spread to the peritoneum but remain confined there. These include:
- Stage IV colorectal cancer with peritoneal spread
- Advanced gastric cancer
- Epithelial ovarian cancer
- Appendiceal tumors with mucinous features
- Peritoneal mesothelioma and pseudomyxoma peritonei
Therefore, each patient undergoes thorough evaluation through imaging, lab tests, and multidisciplinary review to determine suitability.
Clinical Research Confirms Effectiveness
HIPEC is supported by strong clinical research and growing evidence of its impact on survival.
For example, a 2018 New England Journal of Medicine trial showed that adding HIPEC to interval cytoreductive surgery in ovarian cancer extended recurrence-free survival by 3.5 months without increasing adverse events [1].
Similarly, 2019 and 2024 studies in Cancers confirmed the benefits of HIPEC in advanced gastric and colorectal cancers [2, 3]. Earlier publications in the Journal of Clinical Oncology also highlighted its role in improving outcomes for patients with peritoneal spread of cancer [4, 5].
HIPEC in Germany: Advanced Care for Patients
Germany has become one of the most trusted destinations for intraperitoneal chemotherapy (HIPEC). Hospitals in this country combine high surgical expertise with advanced perfusion systems and structured rehabilitation programs.
Patients benefit from:
- Multidisciplinary boards that tailor treatment plans
- Precise temperature-controlled perfusion systems
- Strict adherence to European clinical guidelines
- Comprehensive postoperative support
Moreover, for many patients, cost is a deciding factor. However, Germany guarantees clear pricing without hidden fees. In fact, the HIPEC cost in this country is generally lower than in other developed countries, while the outcomes are similar or even superior.
Comparison of HIPEC Costs
| Country | Average Cost (€) |
| Germany | 55,000-75,000 |
| UK | 83,000-118,000 |
| USA | 112,000-150,000 |
Why Patients Choose Booking Health for HIPEC
Patients choose Booking Health because the company provides more than just access to treatment – it delivers complete support throughout the medical journey.
Booking Health services include:
- Preparation and translation of medical reports.
- Case evaluation by specialized oncologists.
- Visa and travel arrangements for patients and companions.
- Personal coordinators available 24/7.
- Transparent cost agreements with no hidden charges.
Access Your HIPEC Treatment with Booking Health
Booking Health has been coordinating international cancer care for over 12 years. The company partners with leading hospitals in Germany and other countries to make innovative treatments like HIPEC available worldwide. With its focus on evidence-based medicine, patient safety, and transparent processes, Booking Health continues to set new standards in medical tourism.
Booking Health opens the door for international patients to access innovative cancer treatments like HIPEC – contact us today to begin your treatment journey.
References
[1] Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. New England Journal of Medicine. 2018;378(3):230-240. doi: https://doi.org/10.1056/nejmoa1708618 [NEJM]
[2] Helderman R, Löke D, Kok H, et al. Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers. 2019;11(1):78. doi: https://doi.org/10.3390/cancers11010078 [PubMed]
[3] Krell M, Ranjbar S, Gitlin S, et al. Evolution in the Surgical Management of Gastric Cancer Peritoneal Metastases. Cancers. 2024;17(1):100. doi: https://doi.org/10.3390/cancers17010100 [PubMed]
[4] Verwaal VJ, van Ruth S, de Bree E, et al. Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer. Journal of Clinical Oncology. 2003;21(20):3737-3743. doi: https://doi.org/10.1200/jco.2003.04.187 [ASCO Publications]
[5] Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Clinical Oncology. 2012;30(20):2449-2456. doi: https://doi.org/10.1200/jco.2011.39.7166 [ASCO Publications]
